Russia invests 43 million rubles for advancement of breast cancer diagnostics
RVC Biofund, a Russian government enterprise in collaboration with Fund for Modernization and Tech Development, a Russian NGO, invested USD 755,000 in Moscow’s RTM Diagnostics, a breast cancer diagnostic systems developer company. The funds will be utilized by RTM Diagnostics to reform the new screening interface and develop the advanced next-generation diagnostic systems. The devices will be based on the microwave radiothermometry technology and will be superior in safety, sensitivity and screening specificity to the existing systems. It is assumed to be safe for pregnant and breastfeeding women. The new devices will be useful for other medical specialities such as phlebology, urology, and brain and skin cancer. The launch of the new diagnostics is expected by next year and will be available in large number of medical organizations.